Scarica l'app Stockscreener
12.26
1.16%
0.14
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now? - Simply Wall Street
Cathie Wood’s ARK buys Intellia stock, sells Alphabet shares - Investing.com
Tangible book value per share of Intellia Therapeutics, Inc. – HAN:38I - TradingView
Intellia Therapeutics, Inc. (NTLA) Stock Forecasts - Yahoo Finance
No-Moat Intellia Therapeutics Provides Pure-Play, Long-Term Exposure to Gene Editing Therapies - Morningstar
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity - Barchart.com
Could This Cathie Wood Stock Soar in 2027? - theglobeandmail.com
Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA) - Seeking Alpha
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits
Intellia Therapeutics Stock Short Interest Rises to 41.97% - Quiver Quantitative
Does Priority Review Change The Bull Case For Intellia Therapeutics Stock (NTLA)? - simplywall.st
Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha
(NTLA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy - Yahoo Finance
Intellia Therapeutics Inc. (NTLA) Key Financial Ratios – Valuation, Profitability & More - Value Research
symbol__ Stock Quote Price and Forecast - CNN
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances - Yahoo Finance
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - Eastern Progress
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: A Look At Its 95.76% Potential Upside - directorstalkinterviews.com
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform - Stocktwits
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
How (NTLA) Movements Inform Risk Allocation Models - Stock Traders Daily
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia - Investing.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia By Investing.com - Investing.com Australia
Tracking Cathie Wood: Adding to Gene Editing Leader Intellia, Trimming Brera Holdings - moomoo.com
Cathie Wood’s ARK adds Intellia stock, trims Brera Holdings - Investing.com
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? - Yahoo Finance
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Nigeria
Intellia’s Lonvo-z Gains FDA Priority Review for HAE - theglobeandmail.com
Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co. - moomoo.com
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug - Yahoo Finance
NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus
FDA to Decide on First In Vivo Gene Editor Next Year - GenomeWeb
Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative
NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
H.C. Wainwright reiterates Intellia stock rating on FDA review progress - Investing.com
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Nigeria
Citizens reiterates Intellia stock rating on FDA priority review - Investing.com
Citizens reiterates Intellia stock rating on HAE opportunity potential By Investing.com - Investing.com Nigeria
Intellia Announces FDA Acceptance of BLA for Lonvo-z with PDUFA Date March 10, 2027 - TradingView
Intellia Therapeutics Obtains $400M Senior Secured Credit Facility (NASDAQ: NTLA) - Kalkine Media
Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date - AllSci
Intellia Therapeutics stock jumps on FDA priority review By Investing.com - Investing.com Nigeria
Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema - marketscreener.com
Why is Intellia Therapeutics stock rallying today? By Investing.com - Investing.com Australia
NTLA Looks 4.8% Undervalued on GF Value™ Amid FDA Priority Review - GuruFocus
Why is Intellia Therapeutics stock rallying today? - Investing.com
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):